Welcome to our dedicated page for Ernexa news (Ticker: ERNA), a resource for investors and traders seeking the latest updates and insights on Ernexa stock.
Eterna Therapeutics Inc (ERNA) is a pioneering biopharmaceutical company developing off-the-shelf cell therapies using advanced mRNA engineering and iPSC platforms. This page provides investors and researchers with centralized access to official announcements, clinical progress updates, and strategic developments related to the company’s innovative approach to treating solid tumors and complex diseases.
Discover timely updates on ERNA-101’s preclinical advancements, partnership milestones with industry leaders like Factor Bioscience, and regulatory filings. Our curated news collection simplifies tracking of key initiatives in cytokine delivery systems, allogeneic cell therapies, and targeted oncology solutions – critical areas for stakeholders monitoring next-generation immunotherapy platforms.
All content is sourced directly from company releases to ensure accuracy and compliance. Bookmark this page for efficient monitoring of Eterna’s progress in transforming cancer treatment through engineered mesenchymal stem cells and tumor microenvironment modulation technologies.
Eterna Therapeutics (Nasdaq: ERNA) has regained compliance with Nasdaq's continued listing requirements after meeting the market value standard of at least $35 million. The company received formal confirmation on November 12th, 2024, from Nasdaq's Office of General Counsel. Eterna is now positioned as a debt-free, low burn rate, preclinical stage cell therapy company focused on developing ERNA-101 for triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer treatments.
Eterna Therapeutics (NASDAQ: ERNA) has completed a comprehensive financial restructuring to accelerate its developmental activities. The restructuring includes: discontinuing a longstanding lease, resulting in $72 million in savings and reducing monthly cash outflow by $700,000; reducing balance sheet debt; and securing $5 million in PIPE financing.
The company continues advancing ERNA-101, an iPSC-derived mesenchymal stem cells product targeting triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer. Eterna targets IND submissions by 2026.
Eterna Therapeutics Inc. (Nasdaq: ERNA) and Factor Bioscience have announced an exclusive license and collaboration agreement to accelerate the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Eterna has secured a worldwide, exclusive license to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products using Factor's technologies.
The agreement focuses on iPSC-derived mesenchymal stem cells (iMSC) engineered to express specific cytokines. Eterna and Factor will collaborate on data generation to demonstrate efficacy of the licensed drug candidates for development towards IND. Factor is entitled to milestone payments per product candidate and post-commercialization royalties.
This collaboration aims to accelerate the development of therapies targeting solid tumors, rare diseases, and autoimmune disorders.
Eterna Therapeutics Inc. (Nasdaq: ERNA) presents at the ASGCT 27th Annual Meeting on the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features. The innovation aims to improve MSCs' therapeutic potential by addressing issues related to variability, in vivo persistence, and effector function. The presentation highlights the promising role of B2M-KO iMSCs in treating inflammatory diseases.
Eterna Therapeutics Inc. (Nasdaq: ERNA) appoints Dr. Mahendra Rao, an expert in regenerative medicine and cell engineering, to its Scientific Advisory Board. Dr. Rao brings extensive experience in clinical trials and stem cell research to support Eterna's mRNA cell engineering initiatives.
Eterna Therapeutics Inc. (ERNA) is set to present at the ASGCT 27th Annual Meeting on the development of a mRNA-engineered iPSC line mimicking native B2M expression by inserting HLA-E at the B2M locus. The technology aims to enhance safety and efficacy in developing therapeutics, providing potential benefits for the medical field.
Eterna Therapeutics Inc. will present at the ASGCT 27th Annual Meeting on the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features, potentially improving the therapeutic potential of MSCs in treating inflammatory diseases. The presentation aims to address challenges such as variability in therapeutic responses and in vivo persistence of MSCs, offering promising solutions for autoimmune and inflammatory indications.
FAQ
What is the current stock price of Ernexa (ERNA)?
What is the market cap of Ernexa (ERNA)?
